90%Confidence
0Views
FDASource
2026-04-20Date
Summary
Another Fresenius Kabi saline product recall indicates a broader quality failure across its manufacturing lines. This repeated issue may result in significant financial penalties and loss of customer trust.
Actionable: Review investment positions in Fresenius Kabi, anticipating potential earnings impact from recall costs.
AI Confidence: 90%
Data Points
firmFresenius Kabi USA, LLC
classificationClass II
statusOngoing
distributionUS Nationwide , Alaska, and Puerto Rico.
product0.45% Sodium Chloride Injection, USP, 1.125 grams per 250 mL (4.5 mg per mL), 250 mL in a 250 mL freeflex bag, Rx only, Fresenius Kabi USA, LLC ("Fres
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now